Current UK NSC recommendations > Cystic fibrosis (newborn)

The UK NSC recommendation on Cystic fibrosis screening in newborns (currently under review)


This recommendation is currently being reviewed as part of the UK NSC's regular review cycle of all policies.

The review process began in Aug 2016.

Recommendation Systematic population screening programme recommended
Key downloads

Evidence to support continuation or cessation of existing screening programmes should be reviewed regularly. The process for this is currently being revised, which is why this topic does not currently have a review date. The new process will be published in due course. Each programme has an active portfolio of research, evidence and audit to support continual improvement. Find out more about cystic fibrosis screening, as part of the newborn blood spot screening programme in England.


Find general information about population health screening.

More about Cystic fibrosis (newborn)

Cystic Fibrosis (CF) was recognised as a specific entity by Dorothy Andersen of New York in 1938. The condition is characterised by early onset of severe intestinal malabsorption, failure to thrive and recurrent chest infections and pneumonia which, if untreated, leads to death from malnutrition and respiratory failure in infancy or early childhood. Due to improved treatment, particularly with antibiotics and better pancreatic enzyme replacement therapy, average survival has steadily improved to around 37 years.

» Read more about cystic fibrosis on NHS Choices

Screening in the UK

Compare how screening is offered across the UK.


British Association of Perinatal Medicine
Cystic Fibrosis Trust
Faculty of Public Health
Genetic Alliance UK
Institute of Child Health
Royal College of General Practitioners
Royal College of Midwives
Royal College of Paediatrics and Child Health
Royal College of Physicians
Royal College of Physicians and Surgeons of Glasgow
Royal College of Physicians of Edinburgh

The stakeholder groups will be involved when the recommendation is next reviewed. If you think your organisation should be added, please contact us. More information for stakeholders can be found in appendix C of the UK NSC evidence review process.

More options

Go to top